摘要
目的研究NEK2(中心体相关激酶2)在前列腺癌和良性组织中的表达情况及其与前列腺癌预后的相关性。方法运用qRT-PCR检测NEK2在前列腺癌和癌旁组织的表达差异,通过组织芯片免疫组化染色检测的方法检验NEK2在前列腺癌和癌旁组织的表达情况,最后使用Taylor的数据对NEK2进行生物信息学分析。结果qRT-PCR检测NEK2在前列腺癌组织的表达显著高于癌旁组织(6.93±0.15 vs 5.38±0.4,t=6.25,P=0.003),组织芯片免疫组化结果显示NEK2在前列腺癌组织的表达显著高于癌旁组织(5.84±0.56 vs 4.27±0.49,t=5.38,P<0.001),结合Taylor公用数据库分析,NEK2高表达组患者术后的生化复发生存率减少(χ~2=4.33,P=0.037),NEK2高表达组和低表达组在前列腺癌总体生存率上没有明显区别(χ~2=0.27,P=0.605)。结论NEK2参与前列腺癌的发生、发展进程,同前列腺癌发病进程密切相关,通过检测前列腺癌患者NEK2的表达情况,可早期预测生化复发的概率,能够作为判断前列腺癌预后的潜在生物学标志物。
Objective To investigate the expression of NEK2 （ NIMA-related kinase 2） in prostate cancer as well as benign prostatic hyperplasia, and the involvement of NEK2 in the prognosis of prostate caner （PCa）. Methods The different expression of NEK2 in the tissue of prostate cancer and the adjacent benign tissues of prostate were measured by real-time quantitative reverse transeriptase-polymerase chain reaction （QRT-PCR） analysis and immunohositoehemistry analysis, and then bioinformatically analyzed using the Taylor dataset. Results QRT-PCR showed that NEK2 was highly expressed in PCa than in the adjacent benign tissues （6. 93 ± 0. 15 vs 5.38 ± 0. 4, t = 6. 25, P = 0. 003 ）. Immunohositochemistry analysis showed the expression of NEK2 was higher in PCa than in the adjacent benign tissues （5. 84 ±0. 56 vs 4. 27 ±0. 49, t = 5.38, P 〈0. 001 ）. Furthermore, the biochemical recurrence-free time of PCa patients in high NEK2 expression groups significantly reduced （ χ^2 = 4. 33, P = 0. 037 ）. The overall survival time of PCa patients was not correlated to NEK2 expression levels （ χ^2 = 0. 27, P = 0. 605）. Conclusion The above findings suggest that NEK2 is associated with production and development of PCa, and also critically connected with the process of PCa, which indicate that we can predict the probability of the biochemical recurrence-free time by detecting the expression of NEK2 in PCa patients, and NEK2 can also become a potential biomarker for PCa prognosis.
出处
《广州医药》
2017年第2期1-5,共5页
Guangzhou Medical Journal
关键词
前列腺癌
NEK2
生化复发
预后
Prostate cancer
NEK2
Biochemical recurrence
Prognosis
